What we do
Vireo Vaccines International (VVI) develops novel, patent-protected vaccines to improve human and animal health by preventing key diseases such as tuberculosis, Mycobacterium avium complex, and avian influenza. VVI also delivers advanced vaccines and diagnostics aimed at controlling Johne’s disease in cattle, as well as Avian Influenza and Avian Coronavirus (Infectious Bronchitis Virus) in poultry.
Guided by a vision to provide safer and more effective vaccines that enhance both human and livestock health, VVI focuses on designing next-generation solutions that strengthen biosecurity and disease prevention. In addition to its own innovations, the company supports strategic partners by assisting in the testing and development of their products.
VVI’s products and services benefit researchers, farmers, technicians, veterinarians, and veterinary laboratories worldwide — treating every customer as a partner, because their success is our success.
Latest News
Stay updated with out latest developments
Superior Protection from Live-Attenuated Vaccines Directed against Johne’s Disease
VVI has successfully tested a new vaccine against Johne’s disease (paratuberculosis), a chronic infection that affects livestock worldwide. In controlled studies, the vaccine showed 100% protection in goats, demonstrating exceptional efficacy. Based on these results, it is also expected to be effective in sheep and cattle, offering broad value to the livestock industry. Full scientific details are available in the published article linked.
Protective RNA
The induction of an effective immune response is critical for the success of mRNA-based therapeutics. Here, we developed a nanoadjuvant system compromised of Quil-A and DOTAP (dioleoyl 3 trimethylammonium propane), hence named QTAP, for the efficient delivery of mRNA vaccine constructs into cells. Electron microscopy indicated that the complexation of mRNA with QTAP forms nanoparticles with an average size of 75 nm and which have ~90% encapsulation efficiency. The incorporation of pseudouridine-modified mRNA resulted in higher transfection efficiency and protein
Protective RNA
The induction of an effective immune response is critical for the success of mRNA-based therapeutics. Here, we developed a nanoadjuvant system compromised of Quil-A and DOTAP (dioleoyl 3 trimethylammonium propane), hence named QTAP, for the efficient delivery of mRNA vaccine constructs into cells. Electron microscopy indicated that the complexation of mRNA with QTAP forms nanoparticles with an average size of 75 nm and which have ~90% encapsulation efficiency...
Superior Protection from Live-Attenuated Vaccines Directed against Johne’s Disease
Mycobacterium avium subspecies paratuberculosis (M. ap) is the causative agent of paratuberculosis or Johne's disease (JD) in herbivores with potential involvement in cases of Crohn's disease in humans. JD is spread worldwide and is economically important for both beef and dairy industries. Generally, pathogenic ovine strains (M. ap-S) are mainly found in sheep while bovine strains...
Our Promise
Every product we develop meets our highest standards
At Vireovac, we are dedicated to delivering vaccines that are safe, simple, effective, and proven. Each product is developed to the highest standards of quality and safety, designed with both animals and farmers in mind. Our vaccines ensure ease of use and maximum protection, helping reduce infections without compromising host immunity. Backed by rigorous laboratory and field testing, our vaccines have demonstrated their ability to lower infection rates, prevent disease spread, and minimize side effects. Trusted by scientists, industry experts, and farmers alike, Vireovac products represent a reliable and innovative approach to animal health.
Our Projects
Patents
- Inventor: Adel M. Talaat, Bassam Abomoelak and Sarah K. Ward. Immunogenic Compositions Against Tuberculosis. US 8,367,055 B2. (Issued)
- Inventor: Adel M. Talaat. Vaccine Candidates Against Johne’s Disease. US 8,758,77 (Issued)
- Inventor: Adel M. Talaat. Global gene regulators (GGR) as vaccine candidates against paratuberculosis. US 10,544,389 (Issued)
- Inventor: Adel M. Talaat. RNA Biomarkers for Early Diagnosis of Mycobacterial Infections. WARF: P130075US01 (Pending)
- Inventor: Adel M. Talaat and Brock Bakke. A universal vaccine against Infectious Bronchitis Virus, Avian Influenza, Newcastle Disease Virus and Infectious Bursal Disease. WARF: P190239US01 (Pending).
- Inventor: Adel M. Talaat and Sekar Chandrasekar. WARFplex: A novel adjuvant for animal and human vaccines. WARF: P190189US02 (Pending).
- Inventor: Adel M. Talaat and Sekar Chandrasekar. Neutralizing Vaccines Against Human Coronavirus. WARF: P210042US01 (Pending).
- Inventor: Adel M. Talaat and Sekar Chandrasekar. Modified Gene Vaccines Against Avian Coronavirus. WARF: P210169 (Pending).
Research
Effective mosaic-based nanovaccines against avian influenza in poultry.
Kingstad-Bakke BA, Chandrasekar SS, Phanse Y, Ross KA, Hatta M, Suresh M, Kawaoka Y, Osorio JE, Narasimhan B, Talaat AM. Vaccine. 2019 Aug 14;37(35):5051-5058. doi: 10.1016/j.vaccine.2019.06.077.
Superior Protection from Live-Attenuated Vaccines Directed against Johne's Disease.
Shippy DC1, Lemke JJ, Berry A, Nelson K, Hines ME 2nd, Talaat AM5. Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00478-16. doi: 10.1128/CVI.00478-16.
Superior protection elicited by live-attenuated vaccines in the murine model of paratuberculosis.
Ghosh P, Shippy DC, Talaat AM. Vaccine. 2015 Dec 16;33(51):7262-7270. doi: 10.1016/j.vaccine.2015.10.116. Epub 2015 Nov 5.
A single dose polyanhydride-based nanovaccine against paratuberculosis infection
Link
